Vir Biotechnology Signs a License Agreement with Xencor to Utilize Xtend Fc Technology in Antibodies Targeting COVID-19
Shots:
- Vir will get non-exclusive access to Xencor’s Xtend Fc technology for extending the half-life of novel Abs that the company is evaluating for treating patients with COVID-19- a disease caused by novel coronavirus SARS-CoV-2
- Vir will be responsible for research- development- regulatory and commercial activities while Xencor continues to assess the impact of the COVID-19 pandemic on ongoing and planned clinical studies
- In Aug’2019- the two companies collaborated under which Vir got a non-exclusive license to Xtend technology for utilizing it in developing & commercializing Abs targeting influenza and hepatitis B virus infection
Click here to read full press release/ article | Ref: Xencor | Image: VIR Biotechnology
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
